The Push to Redefine Success in Depression Treatment
For too long, the bar for treating depression has been set frustratingly low. A reduction in symptoms — feeling somewhat less hopeless, sleeping a bit better — has often been considered a win. But a growing chorus of psychiatrists is pushing back on that standard, arguing that anything short of full remission represents a failure of care.
A recent piece in Psychiatric Times (April 2026) highlights this shift in clinical thinking, with practitioners urging colleagues to pursue aggressive, goal-directed treatment for people with treatment-resistant depression (TRD) — those who haven't responded adequately to two or more antidepressant trials. The article emphasizes balancing side effect profiles and patient priorities while keeping the target firmly on remission, not just response.
This distinction matters more than it might seem. A "responder" to antidepressant treatment may still carry significant depressive burden — residual symptoms that impair work, relationships, and quality of life. A patient in remission, by contrast, has largely returned to baseline functioning. Clinicians in the piece argue that settling for the former, when the latter is achievable, does patients a disservice.
Where Ketamine Fits Into the TRD Conversation
This renewed focus on remission as the goal is directly relevant to anyone exploring ketamine or esketamine (Spravato) as a treatment option. Ketamine has emerged as one of the most significant developments in TRD care precisely because it works differently than conventional antidepressants — and because it works fast.
Traditional antidepressants modulate serotonin, dopamine, or norepinephrine systems and can take four to eight weeks to show meaningful effects. Ketamine acts on the glutamate system, promoting rapid synaptic plasticity. For many TRD patients, IV ketamine or intranasal esketamine can produce noticeable improvement within hours to days — a timeline that is clinically and personally significant when someone has been suffering for months or years.
The emphasis on true remission — rather than partial symptom reduction — aligns with what ketamine advocates and many patients report: not just feeling "a little better," but a qualitative shift in how they experience their own mood and motivation. Whether that holds long-term depends on maintenance protocols, underlying diagnoses, and supportive care, but the early response profile of ketamine is one reason it has become central to TRD treatment algorithms.
For readers comparing treatment options, this framing is useful. If you've cycled through multiple antidepressants and your provider is comfortable calling modest improvement a success, the emerging clinical consensus — and the availability of newer interventions like ketamine — suggests it may be worth asking for more.
Balancing Efficacy, Side Effects, and Patient Priorities
One of the more nuanced points in the Psychiatric Times discussion involves the trade-off between aggressive treatment and tolerability. Pursuing remission doesn't mean throwing every available option at a patient without regard for side effects or what the patient actually wants. Clinicians emphasize shared decision-making — understanding what a patient's priorities are (returning to work, reconnecting with family, sleeping through the night) and calibrating treatment accordingly.
This is especially relevant for ketamine, which carries its own side effect profile: dissociation during infusions, transient increases in blood pressure, and potential for misuse in certain populations. These aren't trivial concerns. But for many TRD patients, the calculus shifts when conventional options have already failed and the cost of ongoing depression — cognitively, occupationally, relationally — is considered alongside the risks of a new intervention.
Patients considering ketamine should feel empowered to have direct conversations with providers about what remission would look like for them personally, how ketamine fits into an overall treatment plan, and what happens if the initial response fades. The goal isn't just a good first infusion — it's sustained functional recovery.
Key Takeaway
If you've been diagnosed with treatment-resistant depression, the clinical standard is shifting: symptom reduction alone is no longer the accepted finish line. Ask your provider whether your current treatment plan is targeting full remission — and whether rapid-acting options like ketamine or esketamine have been considered as part of that strategy. Partial improvement after multiple medication trials is a signal to escalate care, not accept the status quo.
What to Watch Going Forward
The broader conversation around TRD management is evolving quickly. Beyond ketamine, clinicians are increasingly integrating interventional psychiatry tools — TMS, ECT, and emerging psychedelic-assisted therapies — into TRD care pathways. The common thread is a willingness to move beyond oral antidepressants when those have proven insufficient.
For patients, this is ultimately good news. The clinical culture is becoming more aggressive about pursuing real outcomes, more attentive to individual patient goals, and more open to treatments that operate through different mechanisms. Ketamine sits squarely in that evolution — not as a last resort, but increasingly as an evidence-backed option that belongs earlier in the TRD conversation.
Read the original article at Psychiatric Times.
Share